Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer

Angela Davies, David R Gandara, Primo N Lara, Zelanna Goldberg, Peter Roberts, Derick H Lau

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In the treatment of locally advanced (stage III) non-small cell lung cancer, randomized clinical trials have shown that sequential administration of platinum-based chemotherapy followed by radiotherapy improves outcome compared with radiotherapy alone. More recently, concurrent chemoradiotherapy has been shown to be superior to sequential therapy. Incorporating full-dose chemotherapy into induction or consolidation phases is aimed at the eradication of distant micrometastases. These approaches are currently being examined in clinical trials. The role of neoadjuvant and adjuvant therapy in resectable stage IIIA patients remains controversial. Integration of newer cytotoxic agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) and molecularly targeted agents into the treatment of stage-III patients may result in improved long-term outcomes and is currently under study.

Original languageEnglish (US)
Pages (from-to)10-16
Number of pages7
JournalSeminars in Oncology
Volume29
Issue number3 SUPPL. 12
StatePublished - 2002

Fingerprint

Non-Small Cell Lung Carcinoma
irinotecan
docetaxel
gemcitabine
Radiotherapy
Consolidation Chemotherapy
Neoplasm Micrometastasis
Induction Chemotherapy
Neoadjuvant Therapy
Cytotoxins
Chemoradiotherapy
Paclitaxel
Platinum
Therapeutics
Randomized Controlled Trials
Clinical Trials
Drug Therapy
vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. / Davies, Angela; Gandara, David R; Lara, Primo N; Goldberg, Zelanna; Roberts, Peter; Lau, Derick H.

In: Seminars in Oncology, Vol. 29, No. 3 SUPPL. 12, 2002, p. 10-16.

Research output: Contribution to journalArticle

@article{bf85f54e8a67401d83ac11782915b721,
title = "Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer",
abstract = "In the treatment of locally advanced (stage III) non-small cell lung cancer, randomized clinical trials have shown that sequential administration of platinum-based chemotherapy followed by radiotherapy improves outcome compared with radiotherapy alone. More recently, concurrent chemoradiotherapy has been shown to be superior to sequential therapy. Incorporating full-dose chemotherapy into induction or consolidation phases is aimed at the eradication of distant micrometastases. These approaches are currently being examined in clinical trials. The role of neoadjuvant and adjuvant therapy in resectable stage IIIA patients remains controversial. Integration of newer cytotoxic agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) and molecularly targeted agents into the treatment of stage-III patients may result in improved long-term outcomes and is currently under study.",
author = "Angela Davies and Gandara, {David R} and Lara, {Primo N} and Zelanna Goldberg and Peter Roberts and Lau, {Derick H}",
year = "2002",
language = "English (US)",
volume = "29",
pages = "10--16",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 12",

}

TY - JOUR

T1 - Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer

AU - Davies, Angela

AU - Gandara, David R

AU - Lara, Primo N

AU - Goldberg, Zelanna

AU - Roberts, Peter

AU - Lau, Derick H

PY - 2002

Y1 - 2002

N2 - In the treatment of locally advanced (stage III) non-small cell lung cancer, randomized clinical trials have shown that sequential administration of platinum-based chemotherapy followed by radiotherapy improves outcome compared with radiotherapy alone. More recently, concurrent chemoradiotherapy has been shown to be superior to sequential therapy. Incorporating full-dose chemotherapy into induction or consolidation phases is aimed at the eradication of distant micrometastases. These approaches are currently being examined in clinical trials. The role of neoadjuvant and adjuvant therapy in resectable stage IIIA patients remains controversial. Integration of newer cytotoxic agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) and molecularly targeted agents into the treatment of stage-III patients may result in improved long-term outcomes and is currently under study.

AB - In the treatment of locally advanced (stage III) non-small cell lung cancer, randomized clinical trials have shown that sequential administration of platinum-based chemotherapy followed by radiotherapy improves outcome compared with radiotherapy alone. More recently, concurrent chemoradiotherapy has been shown to be superior to sequential therapy. Incorporating full-dose chemotherapy into induction or consolidation phases is aimed at the eradication of distant micrometastases. These approaches are currently being examined in clinical trials. The role of neoadjuvant and adjuvant therapy in resectable stage IIIA patients remains controversial. Integration of newer cytotoxic agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) and molecularly targeted agents into the treatment of stage-III patients may result in improved long-term outcomes and is currently under study.

UR - http://www.scopus.com/inward/record.url?scp=0036337742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036337742&partnerID=8YFLogxK

M3 - Article

C2 - 12170446

AN - SCOPUS:0036337742

VL - 29

SP - 10

EP - 16

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 12

ER -